Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ASO Visual Abstract: Liver Metastasectomy to Obtain Tumor-Infiltrating Lymphocytes: Technical Considerations and Report on Single-Center Experience.

Annals of surgical oncology·2026

Same author

Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response.

Journal for immunotherapy of cancer·2026

Same author

Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse.

Cell·2026

Same author

Salvage Metastasectomy After Adoptive Cell Transfer for Melanoma: Long-Term Updates.

Annals of surgical oncology·2026

Same author

Liver Metastasectomy to Obtain Tumor-Infiltrating Lymphocytes: Technical Considerations and Report on Single-Center Experience.

Annals of surgical oncology·2026

Same author

The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee.

Journal for immunotherapy of cancer·2025

Search research articles

Related Experiment Video

Updated: Mar 25, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Adoptive T-Cell Therapy for Cancer.

James C Yang¹, Steven A Rosenberg¹

¹Center for Clinical Research, National Cancer Institute, Bethesda, MD, United States.

Advances in Immunology

|March 1, 2016

Summary

Adoptive cell therapy (ACT) shows promise for durable cancer remission by targeting mutated neoantigens. Tumor genomic sequencing reveals new targets, expanding ACT applications for various cancers.

Keywords:

Adoptive cell therapy Immunotherapy Neoantigens T-cell transfer Tumor antigens Tumor infiltrating lymphocytes

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: Mar 25, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

Oncology
Immunology
Genomics

Background:

Immunotherapies, including adoptive cell therapy (ACT), are increasingly effective against metastatic cancers.
ACT has shown success in inducing complete regressions, particularly in melanoma patients.

Purpose of the Study:

To explore the role of neoantigen targeting in adoptive cell therapy (ACT).
To identify new opportunities for expanding ACT to a broader range of cancer types.

Main Methods:

Leveraging insights from successful ACT and other immunotherapies like checkpoint inhibitors.
Utilizing tumor genomic sequencing to identify potential neoantigens for therapeutic targeting.

Main Results:

Immune targeting of mutated neoantigens is crucial for effective ACT.
Tumor genomic sequencing can reveal novel antigens for immune attack.

Conclusions:

The identification of neoantigens through genomic sequencing presents new opportunities for ACT.
Translational research is advancing ACT applications for diverse cancer types.